Linda J Van Eldik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6290515/publications.pdf

Version: 2024-02-01

147726 223716 5,822 48 31 46 citations h-index g-index papers 50 50 50 10616 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
3	Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Frontiers in Genetics, 2014, 5, 88.	1.1	562
4	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
5	The roles of inflammation and immune mechanisms inÂAlzheimer'sÂdisease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 99-109.	1.8	161
6	Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. Journal of Neuroinflammation, 2008, 5, 28.	3.1	156
7	Self-reported memory complaints. Neurology, 2014, 83, 1359-1365.	1.5	151
8	"New Old Pathologies― AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). Journal of Neuropathology and Experimental Neurology, 2016, 75, 482-498.	0.9	130
9	Sex-related responses after traumatic brain injury: Considerations for preclinical modeling. Frontiers in Neuroendocrinology, 2018, 50, 52-66.	2.5	116
10	Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 28.	3.0	106
11	Targeting innate immunity for neurodegenerative disorders of the central nervous system. Journal of Neurochemistry, 2016, 138, 653-693.	2.1	106
12	Glial Activation Links Early-Life Seizures and Long-Term Neurologic Dysfunction: Evidence Using a Small Molecule Inhibitor of Proinflammatory Cytokine Upregulation. Epilepsia, 2007, 48, 1785-1800.	2.6	105
13	Brain pathologies in extreme old age. Neurobiology of Aging, 2016, 37, 1-11.	1.5	94
14	Early Stage Drug Treatment That Normalizes Proinflammatory Cytokine Production Attenuates Synaptic Dysfunction in a Mouse Model That Exhibits Age-Dependent Progression of Alzheimer's Disease-Related Pathology. Journal of Neuroscience, 2012, 32, 10201-10210.	1.7	91
15	Brain arteriolosclerosis. Acta Neuropathologica, 2021, 141, 1-24.	3.9	85
16	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 2-20.	0.9	77
17	Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a $\hat{a} \in \mathbb{T}$ wo-hit $\hat{a} \in \mathbb{T}$ seizure model. Brain Research, 2009, 1282, 162-172.	1.1	76
18	Risk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 201-216.	2.4	69

#	Article	lF	Citations
19	Closed Head Injury in an Age-Related Alzheimer Mouse Model Leads to an Altered Neuroinflammatory Response and Persistent Cognitive Impairment. Journal of Neuroscience, 2015, 35, 6554-6569.	1.7	68
20	Diffuse Brain Injury Induces Acute Post-Traumatic Sleep. PLoS ONE, 2014, 9, e82507.	1.1	64
21	Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 414-418.	1.0	55
22	White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. Neurobiology of Aging, 2014, 35, 2263-2271.	1.5	51
23	Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. Neurolmage: Clinical, 2017, 13, 106-115.	1.4	48
24	Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. Journal of Alzheimer's Disease, 2017, 60, 1-10.	1.2	48
25	Hippocampal Sclerosis but Not Normal Aging or Alzheimer Disease Is Associated With TDP-43 Pathology in the Basal Forebrain of Aged Persons. Journal of Neuropathology and Experimental Neurology, 2016, 75, 397-407.	0.9	40
26	Generation and Behavior Characterization of CaMKIIÎ ² Knockout Mice. PLoS ONE, 2014, 9, e105191.	1.1	38
27	Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic. Journal of Neuroinflammation, 2015, 12, 69.	3.1	36
28	Inhibition of Neuronal p38 \hat{l} ±, but not p38 \hat{l} 2 MAPK, Provides Neuroprotection Against Three Different Neurotoxic Insults. Journal of Molecular Neuroscience, 2015, 55, 509-518.	1.1	35
29	Diffuse traumatic brain injury induces prolonged immune dysregulation and potentiates hyperalgesia following a peripheral immune challenge. Molecular Pain, 2016, 12, 174480691664705.	1.0	34
30	Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. Journal of Alzheimer's Disease, 2018, 64, 1307-1324.	1.2	34
31	Deletion of p38α MAPK in microglia blunts trauma-induced inflammatory responses in mice. Journal of Neuroinflammation, 2019, 16, 98.	3.1	34
32	Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States. Frontiers in Aging Neuroscience, 2016, 8, 15.	1.7	28
33	The effects of mild closed head injuries on tauopathy and cognitive deficits in rodents: Primary results in wild type and rTg4510 mice, and a systematic review. Experimental Neurology, 2020, 326, 113180.	2.0	20
34	Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes. Journal of Neuroinflammation, 2017, 14, 75.	3.1	19
35	Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene. Journal of Neuropathology and Experimental Neurology, 2020, 79, 3-21.	0.9	19
36	MW151 Inhibited IL- $1\hat{1}^2$ Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses. PLoS ONE, 2016, 11, e0149451.	1.1	17

#	Article	IF	CITATIONS
37	Blood Flow Deficits and Cerebrovascular Changes in a Dietary Model of Hyperhomocysteinemia. ASN Neuro, 2019, 11, 175909141986578.	1.5	17
38	Deficiency in p38 \hat{l}^2 MAPK Fails to Inhibit Cytokine Production or Protect Neurons against Inflammatory Insult in In Vitro and In Vivo Mouse Models. PLoS ONE, 2013, 8, e56852.	1.1	16
39	Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. Journal of Neuroimmunology, 2008, 203, 73-78.	1.1	14
40	Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia. GeroScience, 2019, 41, 671-679.	2.1	12
41	Microglial-associated responses to comorbid amyloid pathology and hyperhomocysteinemia in an aged knock-in mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2020, 17, 274.	3.1	12
42	The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism. Journal of Neuroinflammation, 2014, 11 , 175 .	3.1	8
43	Firstâ€inâ€Human Studies of MW01â€6â€189WH, a Brainâ€Penetrant, Antineuroinflammatory Smallâ€Molecule Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development, 2021, 10, 131-143.	Drug 0.8	8
44	Firstâ€inâ€human studies of MW01â€6â€189WH, a brainâ€penetrant, antiâ€neuroinflammatory, small molecule candidate: Phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic studies in healthy adult volunteers. Alzheimer's and Dementia, 2020, 16, e041208.	drug 0.4	1
45	Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology. PLoS ONE, 2022, 17, e0262474.	1.1	1
46	P1-304: An optimized and isoform-selective p38aMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models., 2015, 11, P473-P473.		0
47	P2â€129: A Small Molecule Antiâ€Neuroinflammatory Experimental Therapeutic Inhibited ILâ€1Beta Levels After Traumatic Brain Injury with no Effect on Microglia Physiological Responses. Alzheimer's and Dementia, 2016, 12, P661.	0.4	O
48	[P3–055]: A PLATFORM FOR NOVEL <i>IN VIVO</i> MOLECULAR PROBES FOR ATTENUATION OF SYNAPTIC DYSFUNCTION AND PROINFLAMMATORY CYTOKINE OVERPRODUCTION. Alzheimer's and Dementia, 2017, 13, P951.	0.4	0